Movement Alert｜Agilent Technologies Rises 5.12% in Regular Trading, Completes Acquisition of Biocare Medical to Expand Clinical Diagnostics

Market Focus06-25

On June 25, Agilent Technologies rose 5.12% in regular trading, trading at $138.615/share, with turnover of $60.52 million. The rally was driven by the company's announcement that it has completed its acquisition of Biocare Medical from an investor group led by Excellere Partners and GHO Capital Partners.

Following the transaction, Biocare Medical has been formally integrated into Agilent's Life Sciences and Diagnostics Markets Group. The acquisition is viewed as a strategic expansion of the company's pathology product portfolio, marking a critical step forward in digital pathology platforms and high-precision cancer staining diagnostics. Management maintains an optimistic outlook on integration prospects from a financial perspective.

The move comes amid broader positive momentum for Agilent, which recently reported fiscal Q2 adjusted EPS of $1.49, beating estimates of $1.41 by 5.67%, while revenue of $1.835 billion also topped consensus. The company raised full-year guidance to adjusted EPS of $6.00-$6.10. Additionally, Barclays raised its price target to $150 from $145, maintaining an Overweight rating.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1137359912?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-25 22:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137359912","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Agilent Technologies Rises 5.12% in Regular Trading, Completes Acquisition of Biocare Medical to Expand Clinical Diagnostics","media":"Market Focus","content":"<p><p>On June 25, Agilent Technologies rose 5.12% in regular trading, trading at $138.615/share, with turnover of $60.52 million. The rally was driven by the company's announcement that it has completed its acquisition of Biocare Medical from an investor group led by Excellere Partners and GHO Capital Partners.</p><p>Following the transaction, Biocare Medical has been formally integrated into Agilent's Life Sciences and Diagnostics Markets Group. The acquisition is viewed as a strategic expansion of the company's pathology product portfolio, marking a critical step forward in digital pathology platforms and high-precision cancer staining diagnostics. Management maintains an optimistic outlook on integration prospects from a financial perspective.</p><p>The move comes amid broader positive momentum for Agilent, which recently reported fiscal Q2 adjusted EPS of $1.49, beating estimates of $1.41 by 5.67%, while revenue of $1.835 billion also topped consensus. The company raised full-year guidance to adjusted EPS of $6.00-$6.10. Additionally, Barclays raised its price target to $150 from $145, maintaining an Overweight rating.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Agilent Technologies Rises 5.12% in Regular Trading, Completes Acquisition of Biocare Medical to Expand Clinical Diagnostics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Agilent Technologies Rises 5.12% in Regular Trading, Completes Acquisition of Biocare Medical to Expand Clinical Diagnostics\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-25 22:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 25, Agilent Technologies rose 5.12% in regular trading, trading at $138.615/share, with turnover of $60.52 million. The rally was driven by the company's announcement that it has completed its acquisition of Biocare Medical from an investor group led by Excellere Partners and GHO Capital Partners.</p><p>Following the transaction, Biocare Medical has been formally integrated into Agilent's Life Sciences and Diagnostics Markets Group. The acquisition is viewed as a strategic expansion of the company's pathology product portfolio, marking a critical step forward in digital pathology platforms and high-precision cancer staining diagnostics. Management maintains an optimistic outlook on integration prospects from a financial perspective.</p><p>The move comes amid broader positive momentum for Agilent, which recently reported fiscal Q2 adjusted EPS of $1.49, beating estimates of $1.41 by 5.67%, while revenue of $1.835 billion also topped consensus. The company raised full-year guidance to adjusted EPS of $6.00-$6.10. Additionally, Barclays raised its price target to $150 from $145, maintaining an Overweight rating.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"A","symbol_name":"安捷伦科技","start_time":0,"source_url":"","article_id":"1137359912","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137359912","pubTimestamp":1782398267,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 25, Agilent Technologies rose 5.12% in regular trading, trading at $138.615/share, with turnover of $60.52 million. The rally was driven by the company's announcement that it has completed...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"A":"安捷伦科技"},"translate_title":"动静提示|安捷伦科技常规交易涨5.12%完成收购Biocare Medical拓展临床诊断","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"A":1},"content_text":"On June 25, Agilent Technologies rose 5.12% in regular trading, trading at $138.615/share, with turnover of $60.52 million. The rally was driven by the company's announcement that it has completed its acquisition of Biocare Medical from an investor group led by Excellere Partners and GHO Capital Partners.Following the transaction, Biocare Medical has been formally integrated into Agilent's Life Sciences and Diagnostics Markets Group. The acquisition is viewed as a strategic expansion of the company's pathology product portfolio, marking a critical step forward in digital pathology platforms and high-precision cancer staining diagnostics. Management maintains an optimistic outlook on integration prospects from a financial perspective.The move comes amid broader positive momentum for Agilent, which recently reported fiscal Q2 adjusted EPS of $1.49, beating estimates of $1.41 by 5.67%, while revenue of $1.835 billion also topped consensus. The company raised full-year guidance to adjusted EPS of $6.00-$6.10. Additionally, Barclays raised its price target to $150 from $145, maintaining an Overweight rating.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1137359912","isCrawlerRequest":true}